| 2026-08-10 | 10-Q | 10.2 | Consulting Agreement by and between the Registrant and R. Erik Holmlin, Ph.D., dated May 6, 2026. |
|---|
| 2026-08-10 | 10-Q | 10.1 | Offer Letter by and between the Registrant and Albert A. Luderer, dated May 6, 2026. |
|---|
| 2026-03-23 | 10-K | 10.18 | Supply Agreement by and between the Registrant and Teledyne MEMS (a business unit of Teledyne Digital Imaging, Inc.), dated August 8, 2025. |
|---|
| 2026-03-23 | 10-K | 10.17 | Technology as a Service Agreement by and between the Registrant and Skywater Technology Foundry, Inc. dated May 21, 2025. |
|---|
| 2025-09-18 | 8-K | 10.1 | Form of Securities Purchase Agreement |
|---|
| 2025-08-14 | 10-Q | 10.1 | Sixth Amendment to the Lease by and between the Registrant and The Irvine Company, LLC, dated June 27, 2025. |
|---|
| 2025-03-31 | 10-K | 10.19 | Separation Agreement, effective as of February 20, 2025, by and between Gülsen Kama and the Company. |
|---|
| 2025-02-21 | 8-K | 10.1 | At the Market Offering Agreement, dated February 21, 2025, by and between the Company and H.C. Wainwright, LLC. |
|---|
| 2025-01-06 | 8-K | 10.1 | Form of Securities Purchase Agreement dated January 3, 2025, between Bionano Genomics, Inc. and the purchasers party thereto |
|---|
| 2024-10-31 | 8-K | 10.1 | Form of Securities Purchase Agreement dated October 30, 2024, between Bionano Genomics, Inc. and the purchasers party thereto |
|---|
| 2024-08-07 | 10-Q | 10.17 | Option and Sublicense Agreement by and between the Registrant and Pacific Biosciences of California, Inc. dated February 2, 2016. |
|---|
| 2024-08-07 | 10-Q | 10.16 | License Agreement by and between the Registrant and New York University dated November 4, 2013. |
|---|
| 2024-08-07 | 10-Q | 10.15 | Amendment to Non-Exclusive Patent License Agreement by and between the Registrant and Q Biotechnology CV dated May 1, 2014. |
|---|
| 2024-08-07 | 10-Q | 10.14 | License Agreement by and between the Registrant and Q Biotechnology CV dated May 1, 2014. |
|---|
| 2024-08-07 | 10-Q | 10.13 | Fourth Amendment to the License Agreement by and between Princeton University and the Registrant, dated February 9, 2012. |
|---|
| 2024-08-07 | 10-Q | 10.12 | Second Amendment to the License Agreement by and between Princeton University and the Registrant, dated February 25, 2010. |
|---|
| 2024-08-07 | 10-Q | 10.11 | First Amendment to the License Agreement by and between Princeton University and the Registrant, dated December 17, 2004. |
|---|
| 2024-08-07 | 10-Q | 10.10 | License Agreement by and between Princeton University and the Registrant, dated January 7, 2004. |
|---|
| 2024-08-07 | 10-Q | 10.9 | Manufacturing Services Agreement by and between the Registrant and Paramit Corporation, dated February 18, 2015 |
|---|
| 2024-08-07 | 10-Q | 10.8 | Master Services Agreement by and between the Registrant and Skorpios Technologies, Inc. (f/k/a Novati Technologies, Inc. and f/k/a SVTC Technologies, LLC), dated March 2, 2009, as amended. |
|---|
| 2024-07-08 | 8-K | 10.1 | Form of Securities Purchase Agreement dated July 4, 2024 between Bionano Genomics, Inc. and the purchasers party thereto |
|---|
| 2024-05-28 | 8-K | 10.6 | Letter Agreement Re: Agreement to Redeem Senior Secured Convertible Notes due 2025, dated May 23, 2024, by and between the Company and High Trail Special Situations LLC |
|---|
| 2024-05-28 | 8-K | 10.5 | Registration Rights Agreement, dated May 24, 2024, by and between the Company and the Investors |
|---|
| 2024-05-28 | 8-K | 10.4 | Placement Agency Agreement, dated May 24, 2024, by and between the Company and Canaccord Genuity LLC |
|---|
| 2024-05-28 | 8-K | 10.3 | Subsidiary Guaranty, dated as of May 24, 2024, by BioDiscovery LLC, Lineagen, Inc., Purigen Biosystems, Inc. in favor the Investors |
|---|
| 2024-05-28 | 8-K | 10.2 | Security Agreement, dated as of May 24, 2024, by and among the Company, BioDiscovery, LLC, Lineagen, Inc., Purigen Biosystems, Inc., and JGB Collateral LLC |
|---|
| 2024-05-28 | 8-K | 10.1 | Securities Purchase Agreement, dated May 24, 2024, by and among the Company and the Buyers named therein |
|---|
| 2024-04-05 | 8-K | 10.1 | Form of Securities Purchase Agreement dated April 4, 2024 between Bionano Genomics, Inc. and the purchasers party thereto |
|---|
| 2024-02-28 | 8-K | 10.2 | Amendment to Initial Registered Note issued to the Purchaser, dated February 27, 2024. |
|---|
| 2024-02-28 | 8-K | 10.1 | Letter Agreement between the Company and the Purchaser, dated February 27, 2024. |
|---|
| 2023-11-08 | 10-Q | 10.2 | Transition, Separation and Consulting Agreement dated as of August 11, 2023, by and between Christopher Stewart and the Company. |
|---|
| 2023-11-08 | 10-Q | 10.1 | Employment Agreement, effective as of September 11, 2023, by and between Gülsen Kama and the Company. |
|---|
| 2023-10-11 | 8-K | 10.1 | Securities Purchase Agreement, dated October 11, 2023, by and among the Company and the Purchaser named therein |
|---|
| 2023-05-09 | 10-Q | 10.1 | Amendment No. 1 to Sales Agreement, dated March 9, 2023, by and between the Company and Cowen and Company, LLC. |
|---|
| 2023-04-14 | 8-K | 10.1 | Purchase Agreement, dated April 13, 2023, by and between Bionano Genomics, Inc. and David Barker. |
|---|
| 2023-03-09 | 10-K | 10.22 | Amended and Restated Exclusive License Agreement with Equity, dated July 16, 2021, by and between The Board of Trustees of the Leland Stanford Junior University and Purigen Biosystems, Inc. |
|---|
| 2023-03-09 | 10-K | 10.22A | Amendment No. 1 to the Amended and Restated Exclusive License Agreement Effective the 16th Day of July 2021 Between Stanford University and Purigen Biosystems, Inc., dated November 14, 2022, by and between The Board of Trustees of the Leland Stanford Junior University and Purigen Biosystems, Inc. |
|---|
| 2023-03-09 | 10-K | 10.14 | Lease, dated August 22, 2016, by and between SFF BBC, LLC and Purigen Biosystems, Inc. |
|---|
| 2023-03-09 | 10-K | 10.14A | First Amendment to the Lease by and between Purigen Biosystems Inc, and SFF BBC, LLC, dated August 22, 2016 |
|---|
| 2023-03-09 | 10-K | 10.2A | Forms of grant notice, stock option agreement and notice of exercise under the 2018 Plan. |
|---|
| 2023-03-09 | 10-K | 10.2B | Forms of director grant notice, stock option agreement and notice of exercise under the 2018 Plan. |
|---|
| 2023-03-09 | 10-K | 10.2C | Forms of double-trigger grant notice, stock option agreement and notice of exercise under the 2018 Plan. |
|---|
| 2022-11-28 | 8-K | 10.1 | Bionano Genomics, Inc. 2020 Inducement Plan dated August 20, 2020, as amended. |
|---|
| 2022-03-01 | 10-K | 10.39 | Fifth Amendment to the Lease by and between the Registrant and The Irvine Company, LLC, dated January 12, 2022. |
|---|
| 2022-03-01 | 10-K | 10.38 | Commercial Single-Tenant Lease – Net, dated February 28, 2016, by and between Tesa Beach LLC and BioDiscovery, Inc. |
|---|
| 2022-03-01 | 10-K | 10.36 | Employment Agreement, dated June 14, 2021, by and between the Company and Richard Shippy |
|---|
| 2022-03-01 | 10-K | 10.35 | Stock Restriction Agreement, dated October 8, 2021 and effective October 18, 2021, by and between the Company and Soheil Shams. |
|---|
| 2022-03-01 | 10-K | 10.34 | Employment Agreement, dated October 8, 2021 and effective October 18, 2021, by and between the Company and Soheil Shams. |
|---|
| 2022-03-01 | 10-K | 10.33 | Standard Industrial/Commercial Single-Tenant Lease, made effective as of November 23, 2021, by and between the Company and 6777 Nancy Ridge LLC. |
|---|
| 2022-03-01 | 10-K | 10.7 | Bionano Genomics, Inc. Non-Employee Director Compensation Policy, as amended |
|---|
| 2021-11-04 | 10-Q | 10.1 | Non-Employee Director Compensation Policy, as Amended. |
|---|
| 2021-10-12 | 8-K | 10.1 | Bionano Genomics, Inc. 2020 Inducement Plan dated August 20, 2020, as amended. |
|---|
| 2021-08-04 | 10-Q | 10.1 | Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Bionano Genomics, Inc. 2018 Equity Incentive Plan |
|---|
| 2021-03-23 | 10-K | 10.44 | Fourth Amendment to Loan and Security Agreement, dated December 30, 2020, by and among the Company, Lineagen, Inc., Innovatus Life Sciences Lending Fund I, LP and East West Bank. |
|---|
| 2021-03-23 | 10-K | 10.23 | Fourth Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated February 15, 2021. |
|---|
| 2021-03-23 | 10-K | 10.22 | Third Amendment to the Lease by and between the Registrant and The Irvine Company LLC, dated December 19, 2019. |
|---|
| 2020-11-13 | 10-Q | 10.7 | Employment Agreement, effective as of August 31, 2020, by and between Alka Chaubey and the Company. |
|---|
| 2020-11-13 | 10-Q | 10.6 | Employment Agreement, effective as of September 1, 2020, by and between Christopher Stewart and the Company. |
|---|
| 2020-11-13 | 10-Q | 10.5 | Agreement and Plan of Merger, dated August 21, 2020, by and among the Company, Alta Merger Sub, Inc., Lineagen, Inc. and Michael S. Paul, Ph.D. |
|---|
| 2020-11-13 | 10-Q | 10.4 | Consent and Third Amendment to Loan and Security Agreement, dated August 21, 2020, by and among the Company, Innovatus Life Sciences Lending Fund I, LP and East West Bank. |
|---|
| 2020-08-24 | 8-K | 10.2 | Form of Stock Option Grant Notice and Stock Option Agreement under the Bionano Genomics, Inc. 2020 Inducement Plan. |
|---|
| 2020-08-24 | 8-K | 10.1 | Bionano Genomics, Inc. 2020 Inducement Plan. |
|---|
| 2020-03-10 | 10-K | 10.49 | Second Amendment to Loan Agreement, dated March 6, 2020, by and among the Company, Innovatus Life Sciences Lending Fund I, LP and East West Bank. |
|---|
| 2019-08-08 | 10-Q | 10.1 | Waiver and First Amendment to Loan and Security Agreement, dated June 25, 2019, by and among the Company, Innovatus Life Sciences Lending Fund I, LP and East West Bank. |
|---|
| 2019-03-14 | 8-K | 10.3 | Common Stock Purchase Agreement, dated March 14, 2019, by and among the Company and the Innovatus Investors. |
|---|
| 2019-03-14 | 8-K | 10.2 | Loan and Security Agreement, dated March 14, 2019, by and among the Company, Innovatus Life Sciences Lending Fund I, LP and the Lenders listed on Schedule 1.1 thereto. |
|---|
| 2019-03-14 | 8-K | 10.1 | Common Stock Purchase Agreement, dated March 14, 2019, between the Company and Aspire Capital Fund, LLC. |
|---|
| 2018-11-21 | 8-K | 10.1 | Amendment Agreement, dated November 19, 2018, by and between the Company and Western Alliance Bank, an Arizona corporation. |
|---|